DJIA54036.93 151.83
S&P 5007757.64 47.68
NASDAQ26690.62 342.27
Russell 20003041.60 33.80
German DAX26319.45 179.32
FTSE 10010901.09 33.20
CAC 408714.93 15.22
EuroStoxx 506526.65 14.40
Nikkei 22565606.71 -76.55
Hang Seng25668.03 137.75
Shanghai Comp3940.04 39.69
KOSPI6258.77 -37.61
Bloomberg Comm IDX131.72 1.78
WTI Crude-fut79.99 -3.34
Brent Crude-fut78.18 0.07
Natural Gas2.66 0.03
Gasoline-fut2.99 0.03
Gold-fut4399.70 101.20
Silver-fut63.50 1.71
Platinum-fut1759.60 24.70
Palladium-fut1378.30 2.80
Copper-fut659.10 -12.95
Aluminum-spot3195.00 0.00
Coffee-fut315.90 9.80
Soybeans-fut1176.25 -1.50
Wheat-fut639.75 8.50
Bitcoin64852.21 551.35
Ethereum USD1913.94 10.30
Litecoin45.45 0.01
Dogecoin0.07 0.00
EUR/USD1.1528 -0.0012
USD/JPY158.59 0.99
GBP/USD1.3442 -0.0026
USD/CHF0.8133 0.0057
USD IDX99.54 -0.39
US 10-Yr TR4.647 -0.023
GER 10-Yr TR3.1261 -0.0036
UK 10-Yr TR4.9086 -0.0152
JAP 10-Yr TR2.791 -0.009
Fed Funds3.75 0
SOFR3.65 0.01
High-rise commercial buildings

Sub Markets

Topics

Latest News  + Alternative Assets  | 
Blackstone Closes Record $6.3B Life Sciences Fund

Blackstone Closes Record $6.3B Life Sciences Fund

Blackstone has closed its oversubscribed Blackstone Life Sciences VI (BXLS VI) fund at a $6.3 billion hard cap, making it the firm’s largest life sciences-focused fund to date and nearly 40% larger than its predecessor. 

Since launching its dedicated life sciences platform in 2018, Blackstone has grown BXLS to approximately $15 billion in assets under management as of the fourth quarter of 2025. The platform has supported the development and commercialization of therapies and devices, including LEQVIO, AMVUTTRA, IMBRUVICA and the MiniMed Flex system. 

“Our partnerships with global leaders have produced 34 regulatory approvals of innovative medicines and devices,” said Nicholas Galakatos, Ph.D., Global Head of Blackstone Life Sciences. “This track record highlights how we work successfully with industry trailblazers to help bring their most important products to patients around the world.” 

Over the past 12 months, BXLS has committed nearly $2 billion in new investments, underscoring continued deployment activity. 

Read More News Stories About: Blackstone
Connect

Inside The Story

Blackstone Life Sciences

About Joe Palmisano

Joe Palmisano is Editorial Director for Connect Money, where he brings nearly three decades experience of market insights as a financial journalist, analyst and senior portfolio manager for leading financial publications, advisory firms, and hedge funds. In his role as Editorial Director, Joe is responsible for the selection of content and creation of daily business news covering the financial markets, including Alternative Assets, Direct Investment and Financial Advisory services. Before joining Connect Money, Joe was a financial journalist for the Wall Street Journal, regularly publishing feature stories and trend pieces on the foreign exchange, global fixed income and equity markets. Joe parlayed his experience as a financial journalist into roles as a Senior Research Analyst and Portfolio Manager, writing daily and weekly market analysis and managing a FX and US equity portfolio. Joe was also a contributing writer for industry magazines and publications, including SFO Magazine and the CMT Association. Joe earned a B.S.B.A. in Finance from The American University. He holds the Chartered Market Technician (CMT) designation and is a member of the CFA Institute.

New call-to-action
New call-to-action
New call-to-action